TCR2 Therapeutics initiated with a Hold at EF Hutton

EF Hutton analyst Tony Butler initiated coverage of TCR2 Therapeutics with a Hold rating and $2 price target. The company’s technology seeks to overcome some of the limitations of first generation CAR-Ts, Butler tells investors in a research note. The analyst finds it uncertain whether gavo-cel will have widespread utility in indications outside of mesothelioma and perhaps ovarian cancer.